40 results about "Molecular mimicry" patented technology

The invention belongs to the technical field of biology and specifically relates to a preparation method and an application of a nano antibody capable of specially binding with an anti-deoxynivalenol antibody. The amino acid sequence of the nano antibody is SEQ ID No. 1. The invention also relates to a nucleotide for encoding amino acid. The nano antibody is capable of taking the place of the expensive high-toxicity DON standard substances, and can be applied to the immunological detection of the DON as a competitive antigen or a solid-phase envelope antigen; the nano antibody has immunoreaction characteristic similar to that of natural DON molecule, and is excellent in effect. Compared with the traditional antigen mimic epitopes based on polypeptides and the traditional anti-idiotype antibodies based on IgG, the nano antibody has the characteristics of more stable structure, acid-alkali resistance, high temperature resistance, high detection sensitivity and the like, and therefore, the immunodetection stability of the nano antibody is greatly improved, and meanwhile, the endurance capacity of the nano antibody to the environment is also improved.

The invention relates to a method for constructing a three-dimensional quantitative structure activity relationship model of a B-cell lymphoma-2 (Bcl-2) protein inhibitor and application of the method and belongs to the technical field of biological information. The method comprises the following steps of: according to the known small molecule inhibitor, establishing the three-dimensional quantitative structure activity relationship model of the Bcl-2 protein inhibitor by using a three-dimensional quantitative structure activity relationship technology; and further improving the accuracy of the model by using technologies for analyzing molecular similarity, optimizing molecular conformation, optimizing parameters and the like. By the invention, the Bcl-2 protein binding constants of an active unknown compound can be quickly predicted, and clues of the active compound are acquired within short time. Compared with the conventional high-throughput screening technology, the invention has the advantages of greatly improving screening efficiency and reducing cost.

The invention belongs to the biological technical field, and in particular to preparation and application of nano antibody capable of specifically combining with anti-zearalenone antibody and with an amino acid sequence of SEQ ID No.1; and the invention also relates to the nucleotides encoding the amino acid. The nano antibody of the invention can replace the expensive toxic Zen standard, and can be used in immunological detection of Zen as a competitive antigen or solid coating antigen. The nano antibody has similar immunological properties to natural Zen molecule, and good effect. Compared to a traditional antigen mimicking epitope based on polypeptide and a traditional anti-idiotype antibody based on IgG, the nano antibody has the advantages of more stable structure, acid resistance, alkali resistance, high temperature resistance and high detection sensitivity, so that the immune detection stability has been greatly improved, and the tolerance on the environment has also been improved.

The invention belongs to the technical field of biology, and relates to an antigen mimic epitope of ochratoxin A. The amino acid sequence of the antigen mimic epitope is as follows: KLGFQLHQPSWP, FNLHQPIHNWPL, AQFFQLHSQAYS or DGFQLHTPFSAK. The OTA (Ochratoxin A) antigen mimic epitope provided by the invention can replace an OTA standard product which is high in price and strong in toxicity and is applied to immunological detection on the OTA as a competitive antigen or a solid-phase envelope antigen; sf the antigen mimic epitope has immunoreaction characteristics similar to that of natural OTA molecules, and is very good in effect. The damage of the OTA to the human body health is reduced, the cost is saved, and high application values are provided.

The invention belongs to the field of biotechnologies, and relates to an antigen mimic epitope capable of mimicking fumonisins B1. An amino acid sequence of the antigen mimic epitope is IHQELRYTKDSP. The antigen mimic epitope of FB1 is capable of replacing an FB1 standard substance which is high in price and strong in toxicity, and is applied to immunological detection of the FB1 as a competition antigen or solid-phase envelope antigen. The antigen mimic epitope has an immunoreaction characteristic similar to a natural FB1 molecule, and a good effect. The damage of the FB1 to the health of a human body is reduced, the cost is saved, and high application value is achieved.

The invention discloses a drug virtual screening method and device based on molecular similarity and semi-supervised learning. The method comprises the following steps: S1, collecting a data set to obtain a ligand molecule sample with a biological activity value and a ligand molecule sample without a biological activity value; s2, constructing a regression model by using the ligand molecule sample with the biological activity value obtained in the step S1; s3, calculating the similarity between molecules in the data set; s4, calculating triple loss by utilizing the molecular similarity obtained in the step S3 and the regression model obtained in the step S2; and S5, training the model according to the loss functions obtained in the steps S2 and S4. On the basis of a semi-supervised learning method, a large number of samples without experimental biological activity values are introduced into model training, model prediction values of the samples without the experimental biological activity values are constrained by using molecular similarity and triple loss, and the problem that a large number of samples without the biological activity values cannot effectively participate in model training in an actual application scene is solved.

The invention provides a diethylstilbestrol (DES) mimic antigenic epitope peptide, and a preparation method and an application thereof. Firstly, based on a phage display peptide library technology, ananti-DES monoclonal antibody is used as a target, and a DES antigen mimic epitope having the sequence of YVYPQQK, YVYPPGP or YVYPQSR is selected from a phage random display heptapeptide library. Centering on immune binding characteristics of the antigen mimic epitope, a specific detection method is designed based on enzyme-linked immunosorbent assay, colloidal gold immunochromatography and fluorescent microsphere immunochromatography. The antigenic mimic epitope has similar immunoreactivity characteristics to those of natural DES molecules, can replace an expensive DES standard substance having teratogenic and carcinogenic effects to be used in immunological detection of DES; the detection results are accurate and the sensitivity is high. The harm to human body health in the DES detectionprocess is effectively reduced, and meanwhile, the cost is saved.

The invention belongs to the field of biotechnologies, and relates to an antigen mimic epitope capable of mimicking fumonisins B1. An amino acid sequence of the antigen mimic epitope is TTLQMRSEMADD. The antigen mimic epitope of FB1 is capable of replacing an FB1 standard substance which is high in price and strong in toxicity, and is applied to immunological detection of the FB1 as a competition antigen or solid-phase envelope antigen. The antigen mimic epitope has an immunoreaction characteristic similar to a natural FB1 molecule, and a good effect. The damage of the FB1 to the health of a human body is reduced, the cost is saved, and high application value is achieved.

The invention belongs to the field of biotechnologies and relates to a dodecapeptide antigen mimic epitope for FB1 (fumonisins B1). The amino acid sequence of the dodecapeptide antigen mimic epitope is SMLNDYRDYTTH. The FB1 antigen mimic epitope can substitute for an FB1 standard substance which is expensive and high in toxicity, can serve as a competitive antigen or a solid-phase coating antigen to be applied to immunological detection of the FB1, has immunoreaction characteristics similar to those of natural FB1 molecules and is very good in effect. The harm caused by the FB1 to human health is reduced, the cost is saved, and the dodecapeptide antigen mimic epitope has the very high application value.